NICE is unable to make a recommendation about the use in the NHS of daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma because no evidence submission was received from Janssen-Cilag. The company has confirmed that it does not intend to make a submission.
A technology appraisal of daratumumab with bortezomib and dexamethasone for this population is currently in progress.
If NHS organisations wish to consider daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma, they should follow the advice on rational local decision-making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
NICE will review the position at any point if the company decides that it wants to make an evidence submission.